Executive Virtual Roundtable •
De-Risking capital execution in life sciences
Where life sciences capital projects break — and how leaders are de‑risking execution
Director-level roundtable on capital execution across GMP expansion programs — where CQV validation challenges, schedule compression, and multi‑vendor coordination issues meet the reality of pharma capital projects and life sciences facility expansion.
Executive virtual roundtable
Date: Tuesday, April 7
Time: 12:00 PM – 1:00 PM ET
Curated for leaders responsible for capital execution.
Hosted by Nathan Roman.
Inside the roundtable
- Where life sciences capital projects consistently lose time, momentum, and control
- CQV and validation workforce shortages that put pharma capital projects at risk
- Schedule compression and late‑stage validation risk in new facility builds and expansions
- Multi‑vendor coordination breakdowns across EPCM, OEMs, and CQV partners
- How senior leaders are de‑risking capital execution life sciences programs in 2026
You’re already dealing with these pressures. This conversation is with peers who are, too.
Nathan Roman
Founder & Principal
VMS
Clayton Newman
CEO
Stirling Ultracold
Scott Masiella
Commercialization Leader
Stirling Ultracold
Joanne Meloro
Director
BW Design Group
Tommy O'Donnell
VP, Quality & Validation
7x Inc 500/5000
David Garonzik
Global Sales Manager
Validated Cloud
Nathan Roman
Founder & Principal
VMS
Tommy O'Donnell
VP, Quality & Validation
7x Inc 500/5000
Clayton Newman
CEO
Stirling Ultracold
Scott Masiella
Commercialization Leader
Stirling Ultracold
Rick Saunders
Director
Rees Scientific
David Garonzik
Global Sales Manager
Validated Cloud
Who this roundtable is for
Designed for experienced professionals actively involved in capital execution in life sciences — those who own outcomes, not just inputs.
- Capital project leaders overseeing portfolios of life sciences facility expansion and modernization
- Engineering and facilities leaders accountable for scope, schedule, and technical risk
- Validation and CQV leaders managing multi‑site, multi‑vendor validation programs
- Manufacturing leadership preparing to receive and operate new assets and lines
- Operations executives responsible for start‑up readiness and regulatory inspection outcomes
If you are adjacent to capital execution but not directly responsible for outcomes, this session is unlikely to be the right fit.
The Life Sciences Capital Forum
The Life Sciences Capital Forum is an executive roundtable series focused on capital execution across modern GMP programs.
Roundtables that matter
- Closed‑door, moderated executive roundtables
- Focused on capital execution, CQV, and operational readiness
- Built for leaders accountable for schedule, quality, and compliance
- Structured as an ongoing series, not one‑off broadcasts
What this session covers
Grounded in active life sciences capital projects — not theory — this roundtable distills what operators are actually seeing across their portfolios.
Where projects lose momentum
Real examples of where life sciences capital projects fall behind: scope creep, decision latency, and late‑surfacing CQV issues that erode float and push operational readiness to the edge.
Workforce & validation constraints
How CQV and validation resource shortages are reshaping capital execution life sciences strategies — and what leaders are doing to avoid late‑stage validation risk on critical assets.
Coordination & lessons learned
Multi‑vendor coordination across EPC, OEMs, integrators, and CQV teams — where it breaks, how leaders are tightening interfaces, and the specific practices they are carrying forward into the next wave of pharma capital projects.
Why this conversation matters now
Life sciences capital projects are accelerating. Biologics, CGT, and sterile expansions are competing for the same constrained validation talent, while regulatory expectations and launch timelines continue to tighten.
Leaders are being asked to scale capital programs under pressure — compressing schedules, absorbing scope, and protecting compliance exposure — without the luxury of perfect resourcing or flawless vendor execution.
- Capital investment is accelerating — portfolios are expanding, not shrinking.
- Timelines are compressing, leaving little room for late‑stage CQV or validation surprises.
- Talent is constrained across engineering, automation, and validation disciplines.
- Regulatory pressure is increasing, with less tolerance for start‑up instability.
- The organizations that master capital execution now will define capacity for the next decade.
This is the reality leaders in the room are navigating right now. The roundtable is designed to meet that reality head‑on.
Format: peer discussion, not presentations
- Moderated, conversational roundtable with senior leaders
- No slides, no marketing decks, no scripted demos
- No selling — this is not a vendor webinar
- Recorded to create thought leadership for the Life Sciences Capital Forum
- Focus on practical patterns, decision frameworks, and lessons learned
You should expect a candid, off‑PowerPoint discussion framed by a light moderation — not a broadcast to a broad, anonymous audience.
Who will be in the room
Featuring senior leaders across the life sciences ecosystem responsible for bringing capital programs online and into compliant operation:
- Perspectives from those actively delivering large‑scale capital programs
- Operators inside real projects — not outside observers
- Voices from owner organizations, CQV partners, and integrators
- Leaders with direct accountability for capital execution outcomes
Names and organizations are not promoted publicly. The emphasis is on the quality of conversation, not on speaker marketing.
Private viewing room
Life Sciences Capital Forum — Roundtable Access
De‑Risking Capital Execution in Life Sciences — an executive‑level, recorded discussion for leaders responsible for life sciences capital projects, CQV validation, and operational readiness.
Reserved for registered participants of the Life Sciences Capital Forum.
What you’re watching
An executive roundtable discussion on de‑risking capital execution in life sciences — recorded live with senior leaders across the industry.
- Peer‑level perspectives from operators inside active projects
- Real examples from pharma capital projects and facility expansions
- Focus on what is actually working in capital execution life sciences environments
For the best experience, view in a quiet environment and treat this as an executive briefing, not background content.
Key discussion themes
Use these themes to anchor follow‑up conversations with your own teams and partners.
Capital execution risk
Patterns of where programs derail, and how leaders are re‑sequencing scope and decisions to keep risk visible and manageable.
Workforce & validation constraints
Strategies to absorb CQV and validation bottlenecks without compromising start‑up dates or inspection readiness.
Multi‑vendor coordination
How teams are clarifying interfaces, decision rights, and accountabilities across EPC, OEM, CQV, and operations stakeholders.
Lessons & future outlook
What leaders on the roundtable are carrying forward into the next cycle of life sciences facility expansion and modernization.
Continue the conversation
The Life Sciences Capital Forum is an ongoing series of executive‑level roundtables on capital execution, CQV validation challenges, and life sciences capital projects. If you’d like to stay close to future sessions, you can indicate your interest by registering.
- Invitations to future executive roundtables
- Occasional briefings on emerging capital execution themes
- Priority consideration for sessions aligned to your portfolio
Stay connected to the Forum
If you didn’t request ongoing updates during registration, you can do so here.
We keep communication infrequent and focused on substantive capital execution insights.
Next steps
Use this discussion as a prompt for internal reviews of your current life sciences capital projects. Identify where CQV, validation, or coordination risks look similar — and where you may need to adjust execution strategy.